Crinetics Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald

Dow JonesSep 16 23:46 · Ratings

Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target

Analyst UpgradesSep 16 23:36

Crinetics Pharmaceuticals Analyst Ratings

BenzingaSep 16 23:35 · Ratings

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireSep 11 04:40

Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Yahoo FinanceSep 5 13:07

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Yahoo FinanceAug 30 04:05